In Episode 17, we talk about approval of Ayvakit for the treatment of specifically mutated GIST, FDA statement regarding the risk of cancer while taking Belviq, and approval of Mycamine for pediatric patients less than 4 months. We also go over two topics this week, the FDA fight against e-cigarettes, and California potentially becoming the next big generic manufacturer. Don't forget to share and subscribe!